As stated by Zacks Investment Research, Wall Street brokerages foretell how Bellicum Pharmaceuticals Inc will post about $200,000 in sales for the present year. Incomes for Bellicum Pharmaceuticals have been approximated by 2 experts. According to them, the greatest income approximation is $300,000, while the lowest is $100,000. Sales for the same quarter of the previous year, for Bellicum Pharmaceuticals, were $360,000. This implied a negative growth rate of 44.4% as compared to the previous year. It is expected that Bellicum Pharmaceuticals, on the 6th of August, will publicize their following quarterly earnings report.
The latest quarterly earnings results were posted on the 7th of May, by Bellicum Pharmaceuticals. The company defeated Zack’s consensus approximation of $0.83 with $0.28, as Bellicum Pharmaceuticals’ reported earning per each share for the quarter, was $0.55. Relative to the consensus approximation of $0.2 million, the revenue generated for the quarter for Bellicum Pharmaceuticals was $0.52. Bellicum Pharmaceuticals reported a negative net margin by 6,729%. The company also reported a negative return on equity of 123%.
Recently, In BLCM, numerous hedge funds and institutional investors have increased or decreased their stakes. In the final quarter, Great-West Life Assurance Co. purchased a new stake worth $35000 in Bellicum Pharmaceuticals. In the same company, in the 1st quarter, BNP Paribas Arbitrage SA raised its position in shares by 78.9%, now owns 12,567 shares worth $42000 following the purchase of 5,544 new shares in the last quarter. A stake worth $48000 was purchased by Jane Street Group LLC in shares of the same company in the final quarter. Paloma Partners Management Co and Eagle Ridge Investment Management bought new stakes worth $65,000 and $67,000, in the final and the 1st quarter, respectively.
BLCM stock shares reached $2.31 on Friday’s trading hours after they traded down $0.18. Relative to its average volume of 392,445 shares, the trading volume of the company was 380,705.